{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:22:10Z","timestamp":1793762530183,"version":"4.6.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI124429"],"award-info":[{"award-number":["AI124429"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL134839"],"award-info":[{"award-number":["HL134839"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-AI-045008"],"award-info":[{"award-number":["P30-AI-045008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI124429"],"award-info":[{"award-number":["AI124429"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HL134839"],"award-info":[{"award-number":["HL134839"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P30-AI-045008"],"award-info":[{"award-number":["P30-AI-045008"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.ymthe.2021.06.004","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T19:58:33Z","timestamp":1622836713000},"page":"3293-3304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":307,"title":["Highly efficient CD4+ T\u00a0cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs"],"prefix":"10.1016","volume":"29","author":[{"given":"Istv\u00e1n","family":"Tomb\u00e1cz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorottya","family":"Laczk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna","family":"Shahnawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika","family":"Natesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Yadegari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler E.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad-Gabriel","family":"Alameh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Shuvaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L.","family":"Mui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Muzykantov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Pardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Weissman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Parhiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.06.004_bib1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4161\/bioe.24666","article-title":"Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering","volume":"4","author":"Pranchevicius","year":"2013","journal-title":"Bioengineered"},{"key":"10.1016\/j.ymthe.2021.06.004_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/pcmedi\/pby011","article-title":"Recent updates on cancer immunotherapy","volume":"1","author":"Liu","year":"2018","journal-title":"Precis. Clin. Med."},{"key":"10.1016\/j.ymthe.2021.06.004_bib3","series-title":"Immunotherapy in Translational Cancer Research","first-page":"101","article-title":"Immunotherapy with Genetically Modified T Cells","author":"Schultz","year":"2018"},{"key":"10.1016\/j.ymthe.2021.06.004_bib4","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.06.004_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00018-018-2935-4","article-title":"mRNA as novel technology for passive immunotherapy","volume":"76","author":"Schlake","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2021.06.004_bib6","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3389\/fimmu.2017.01668","article-title":"The Future of Immunotherapy: A 20-Year Perspective","volume":"8","author":"Wraith","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib7","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.molonc.2015.10.012","article-title":"CAR T-cell immunotherapy: The path from the by-road to the freeway?","volume":"9","author":"Whilding","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib8","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","article-title":"Making CAR T Cells a Solid Option for Solid Tumors","volume":"9","author":"Schmidts","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T Cell Therapy for Cancer in the Clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/cgt.2016.82","article-title":"The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective","volume":"24","author":"Junghans","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","article-title":"The Emerging Role of In\u00a0Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy","volume":"27","author":"Foster","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.06.004_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2013-08-521229","article-title":"Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T\u00a0cells from HIV-1 infection","volume":"123","author":"Didigu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2021.06.004_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13578-017-0174-2","article-title":"Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T\u00a0cells from HIV-1 infection","volume":"7","author":"Liu","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ymthe.2021.06.004_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41587-019-0137-8","article-title":"Gene editing for immune cell therapies","volume":"37","author":"Bailey","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2018.10.015","article-title":"PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake","volume":"291","author":"Parhiz","year":"2018","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2021.06.004_bib19","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1073\/pnas.1912012117","article-title":"Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier","volume":"117","author":"Marcos-Contreras","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.06.004_bib20","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2021.06.004_bib21","first-page":"523","article-title":"Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: implication for therapeutic RNA development","volume":"10","author":"Karik\u00f3","year":"2007","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.ymthe.2021.06.004_bib22","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib23","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1091\/mbc.10.3.677","article-title":"Cluster of differentiation antigen 4 (CD4) endocytosis and adaptor complex binding require activation of the CD4 endocytosis signal by serine phosphorylation","volume":"10","author":"Pitcher","year":"1999","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ymthe.2021.06.004_bib24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/jbm.a.36315","article-title":"Optimization and comparison of CD4-targeting lipid-polymer hybrid nanoparticles using different binding ligands","volume":"106","author":"Cao","year":"2018","journal-title":"J.\u00a0Biomed. Mater. Res. A"},{"key":"10.1016\/j.ymthe.2021.06.004_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jconrel.2010.06.029","article-title":"Induction of therapeutic gene silencing in leukocyte-implicated diseases by targeted and stabilized nanoparticles: a mini-review","volume":"148","author":"Peer","year":"2010","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2021.06.004_bib26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/emmm.201707678","article-title":"mRNA mediates passive vaccination against infectious agents, toxins, and tumors","volume":"9","author":"Thran","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymthe.2021.06.004_bib27","series-title":"Novel Lipids and Lipid Nanoparticle Formulations for Delivery of Nucleic Acids. Patent WO2017075531A1, filed October 28, 2016, and published May 4, 2017","author":"Ansell","year":"2017"},{"key":"10.1016\/j.ymthe.2021.06.004_bib28","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fimmu.2018.00974","article-title":"T Cell Co-Stimulation: Inhibition of Immunosuppression?","volume":"9","author":"Sundqvist","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/imm.12770","article-title":"T-cell regulation through a basic suppressive mechanism targeting low-density lipoprotein receptor-related protein 1","volume":"152","author":"Panezai","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2021.06.004_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/nano10020190","article-title":"Immunological and Toxicological Considerations for the Design of Liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ymthe.2021.06.004_bib31","doi-asserted-by":"crossref","first-page":"e1003586","DOI":"10.1371\/journal.pcbi.1003586","article-title":"Mathematical modeling reveals kinetics of lymphocyte recirculation in the whole organism","volume":"10","author":"Ganusov","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib32","doi-asserted-by":"crossref","first-page":"18036","DOI":"10.1073\/pnas.1211717109","article-title":"Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4+ and CD8+ T\u00a0cells","volume":"109","author":"Mandl","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.06.004_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3389\/fonc.2019.00297","article-title":"Gene Therapy Leaves a Vicious Cycle","volume":"9","author":"Goswami","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.24791","article-title":"Gene Therapies for Cancer: Strategies, Challenges and Successes","volume":"230","author":"Das","year":"2015","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1478-811X-6-3","article-title":"RNA interference-mediated gene silencing in murine T\u00a0cells: in\u00a0vitro and in\u00a0vivo validation of proinflammatory target genes","volume":"6","author":"Gust","year":"2008","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ymthe.2021.06.004_bib37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1096\/fj.05-4651fje","article-title":"Efficient nonviral gene delivery into primary lymphocytes from rats and mice","volume":"20","author":"Goffinet","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2021.06.004_bib38","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2362.2006.01626.x","article-title":"T-lymphocyte subset distribution in human spleen","volume":"36","author":"Langeveld","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2021.06.004_bib40","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2021.06.004_bib41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.addr.2020.04.002","article-title":"Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes","volume":"159","author":"Veiga","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2021.06.004_bib42","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.ymthe.2017.03.001","article-title":"Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes","volume":"25","author":"Mizrahy","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib43","doi-asserted-by":"crossref","first-page":"1606944","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In\u00a0Vivo Delivery of Messenger RNA to B Lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2021.06.004_bib44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/1061186X.2016.1172587","article-title":"Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles","volume":"24","author":"Ramishetti","year":"2016","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.ymthe.2021.06.004_bib45","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2021.06.004_bib46","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1021\/acsnano.5b02796","article-title":"Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles","volume":"9","author":"Ramishetti","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2021.06.004_bib47","doi-asserted-by":"crossref","first-page":"E5859","DOI":"10.1073\/pnas.1805358115","article-title":"Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters","volume":"115","author":"McKinlay","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2021.06.004_bib50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nbt.3467","article-title":"Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity","volume":"34","author":"Karpinski","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2021.06.004_bib51","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In\u00a0Vitro-Transcribed mRNA","volume":"15","author":"Baiersd\u00f6rfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2021.06.004_bib52","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.06.004_bib53","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1002\/anie.201203263","article-title":"Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in\u00a0vivo","volume":"51","author":"Jayaraman","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ymthe.2021.06.004_bib54","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/acs.bioconjchem.5b00641","article-title":"Vascular Accessibility of Endothelial Targeted Ferritin Nanoparticles","volume":"27","author":"Khoshnejad","year":"2016","journal-title":"Bioconjug. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621003105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621003105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T18:53:16Z","timestamp":1714589596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621003105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1525001621003105"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.004","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Highly efficient CD4+ T\u00a0cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}